Stay updated with our latest developments, research breakthroughs, and company announcements
Bionsight has been selected for the 2026 Seoul Bio Hub–Samsung Bioepis Open Innovation Program, recognized for its AI- and DIA-MS-based proteome-wide target discovery platform.
Read more →
Bionsight's CSO Namgil Lee attended the BIO International Convention 2026 in San Diego, promoting the company and pursuing partnering opportunities with global pharmaceutical companies.
Read more →
Bionsight presented two posters at ASMS 2026, sharing its latest mass spectrometry–based research with the global proteomics community.
Read more →
Bionsight has been selected to pitch at the BioTools Innovator 2026 Road Tour, joining roughly 15% of global applicants invited to present to investors and industry leaders.
Read more →We are excited to launch our new website and share our vision for revolutionizing drug discovery through AI and chemoproteomics.
Read more →Selected for the “Scale-up TIPS” program by the Ministry of SMEs and Startups
Read more →Successfully raises Series A funding for drug discovery innovation
Read more →Bionsight selected as the finalist team in 2022 Merck Research Grants.
Read more →